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ABSTRACT 
Antiplatelet therapy with aspirin and clopidogrel is a cornerstone in cardiovascular 
prevention and lowers cardiovascular mortality and morbidity in patient with coronary 
artery disease (CAD). Mental stress and physical exertion can trigger acute coronary 
events and prothrombotic responses to stress may contribute to such triggering. Platelet 
activation seems to contribute to the pathogenesis of preeclampsia. 
 
The dose- and time-dependence of antiplatelets effects of aspirin (37.5 mg/day, 320 
mg/day and a single dose of 960 mg) were studied in 15 male healthy volunteers. The 
variable most sensitive to inhibition by aspirin was arachidonic acid (AA)-induced 
platelet aggregation in platelet rich plasma, followed by serum TxB2. The urinary 
excretion of 11-dehydro-TxB2 was less markedly, but dose-dependently reduced by 
aspirin. The effectiveness of aspirin is thus highly dependent on the assay method used. 
There was limited inhibition by aspirin of collagen and AA-induced platelet 
aggregation in hirudinized whole blood and there was recovery of platelet function in 
whole blood within a normal 24 h dosing interval in healthy volunteers. 
 
The effects of clopidogrel treatment on exercise-induced platelet activation were 
examined in 15 healthy volunteers who performed an exhaustive exercise test, and in 
31 aspirin treated patients with stable CAD who performed a symptom limited exercise 
test in a randomized, double-blind, placebo controlled study. Strenuous exercise evoked 
multicellular activation in vivo and promoted a prothrombotic state. Clopidogrel 
treatment inhibited platelet and platelet-leukocyte aggregation evoked by ADP and 
thrombin (which releases ADP from platelets) stimulation in vitro but the acute 
prothrombotic response to exercise was little influenced by clopidogrel treatment in 
both aspirin treated CAD patients and healthy volunteers. This indicates that the P2Y12 
receptor is not likely to be of major importance for “stress-induced” platelet activation.  
 
The urinary excretion of 11-dehydro-TxB2 (TxM) reflects platelet activity in vivo. The 
present work improved the methodology for immunological measurements of TxM in 
urine, and also showed that such measurements may be performed in plasma for the 
evaluation of platelet activity. This method showed excellent agreement with the gold 
standard method based on gas chromatography-mass spectrometry. 
 
Urinary TxM increased throughout normal pregnancy with the highest excretion 3-7 
days postpartum. In 28 patients at high risk of suffering preeclampsia urinary TxM was 
elevated compared to the healthy pregnant women already before gestational week 13. 
Low-dose aspirin treatment (75 mg once daily) effectively inhibited platelet-dependent 
thromboxane production early in pregnancy in high risk patients, but urinary TxM 
increased later during pregnancy. The results support a role for thromboxane in 
preeclampsia, and suggest that aspirin treatment should be initiated earlier than has 
been the case in studies which show only modest protective effects of low-dose aspirin. 
 
This thesis shows that both aspirin and clopidogrel have limitations as antithrombotic 
agents. Some patients at risk may not benefit from adequate aspirin protection against 
cardiovascular events. One explanation for this result may be our finding of a recovery 
of platelet function 24 hours after dosing and that pronounced AA-induced platelet 
aggregation persists in whole blood despite aspirin treatment. “Stress-induced” platelet 
activation is little influenced by treatment with aspirin and clopidogrel. This 
information about treatment with aspirin and clopidogrel might be useful in shaping 
more efficient antithrombotic therapy for patients at high cardiovascular risk. 
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1 INTRODUCTION 
1.1 GENERAL BACKGROUND 
Cardiovascular disease (CVD) is the leading cause of death in the United States and 
Western Europe [1]. The discovery of the importance of platelets in CVD has changed 
therapy. Antiplatelet agents, especially acetylsalicylic acid (aspirin), are today 
cornerstones in the prevention of atherothrombotic complications.  
 
Atherosclerosis is a chronic inflammatory disease [2] and intravascular thrombosis 
occurs when an atherosclerotic plaque rupture or fissure leads to exposure of platelet 
activating and procoagulant elements [3-6]. Platelets interact with various endothelial 
and inflammatory mechanisms [6] and a critical component of atherothrombosis may 
be the activation of platelets by inflammatory triggers. Mental stress and physical 
exertion activate platelets and prothrombotic responses to “stress” may contribute to the 
triggering of acute coronary events [7-13]. In addition, frequent episodes of stress with 
haemostatic activation may contribute to the slow progression of atherosclerosis 
[13,14]. 
 
Platelets are essential for primary hemostasis and repair of the endothelium [4].The 
ability of platelets to participate in both normal hemostasis and atherothrombosis 
depends on their adhesive properties and their capacity to become activated and release 
various compounds with biological activities in response to various stimuli [15]. 
 
Aspirin (i.e., low-dose acetylsalicylic acid) and clopidogrel are widely used and very 
well documented antiplatelet drugs that lower cardiovascular morbidity and mortality 
[16-18]. However, the occurrence of adverse ischemic events despite antiplatelet 
treatment is a serious clinical problem which, in part, may be related to a poor 
treatment response. There is variability in responses to treatment with aspirin and 
clopidogrel and the possibilities of tailoring antiplatelet therapy based on platelet 
function testing is a very active research field at present. However, the evaluation of 
antiplatelet treatment with different platelet function tests has not yet been 
sufficiently documented for clinical use [19-21]. The relationship between surrogate 
markers for platelet function and clinical events is a critical issue. Thrombosis 
involves multiple signalling pathways and treatment failure is not synonymous with 
drug resistance [19,20]. There are thus no agreed definitions of aspirin or clopidogrel 
“resistance” and the mechanisms of resistance as well as how to tailor the treatment  
remains incompletely defined [21,22]. 
 
Preeclampsia is a multisystem disorder in which platelet activation seems to contribute 
to the pathogenesis [23,24]. Several studies have therefore evaluated the effects of 
aspirin treatment in the primary prevention of preeclampsia, but the results have been 
relatively disappointing [25].  
 
The present work concerns platelet function and the effects of antiplatelet treatment in 
healthy volunteers, in patients with CVD, and in pregnant women at high risk of 
suffering preeclampsia. 
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1.2 PLATELET PHYSIOLOGY 
Platelets are small discoid cell fragments which circulate in large numbers (200-300 
x109/L - under normal conditions). Platelets are shed from megakaryocytes in the bone 
marrow. Their lifespan is normally 9-11 days and they have a median volume of 7-9 fL 
[26]. The main physiological function of platelets is to arrest bleeding from damaged 
blood vessels through the formation of hemostatic plugs. Platelets are sequestered in 
the spleen which retains approximately one-third of the body’s platelets in a platelet 
pool [27]. There are three different platelet specific secretory granules: α-granules, 
dense granules and lysosomes. Examples of proteins stored in α-granules are P-
selectin, von Willebrand factor (vWF). β-thromboglobulin (β -TG), fibrinogen, 
GPIIb/IIIa, Factor V, Factor X, and CD40 ligand. The dense granules contain 
adenosine-diphosphate (ADP), serotonin and Ca2+ which promote platelet activation. 
Lysosomes contain hydrolytic enzymes.    
 
The platelet cytoplasmic membrane is composed of a bilayer of polarized 
phospholipids containing arachidonic acid (AA) which is released and converted to 
thromboxane A2 (TxA2) during platelet activation. The external layer of the platelet 
membrane contains numerous glycoproteins (e.g., GPIIb/IIIa, GPIb/IX/V, and GPVI) 
which act as receptors for various ligands and are essential for adhesion and 
aggregation. GPIIb/IIIa is the most abundant receptor and belongs to the integrin family 
of heterodimeric adhesion molecules [28]. A normal platelet contains approximately 80 
000 GPIIb/IIIa complexes [29]. Upon activation GPIIb/IIIa undergoes a conformational 
change enabling the binding of its principal ligand fibrinogen which is crucial for 
platelet aggregation. The cytoplasmatic membrane invaginates into the platelet to form 
the open canalicular system. This system is a storage site for membrane receptors, 
enlarges the platelet surface area and facilitates the release of granular contents. The 
platelet also has a dense tubular system which is a site for Ca2+ storage and various 
enzymatic activities including those required for prostaglandin synthesis. 
 
1.3 PLATELET ACTIVATION 
At a site of vascular injury, platelets are exposed to thrombogenic components of the 
subendothelium (collagen, vWf, fibronectin and tissue factor; TF). This is the first step 
of primary hemostasis. The endothelium normally has antithrombotic properties, but 
inflammation, infection and metabolic alterations decrease the antithrombotic potential 
of endothelial cells normally mediated by compounds like prostacyclin (PGI2) and 
nitric oxide NO [15]. 
  
One of the most important ligands for adhesion is the multimeric subendothelial vWF 
which binds to a platelet receptor; membrane bound glycoprotein (GP1b-IX-V) [30]. 
This adhesion leads to shape change of the platelet from a smooth disc to a tiny sphere 
with pseudopodia, and spreading of the platelet on the damaged vessel wall. Signals 
from adhesion receptors act in synergy with signals from agonists like TxA2, adrenaline 
and ADP through a network of signalling pathways. TxA2 and ADP provide important 
positive feedback to reinforce platelet aggregation. ADP elicits its effects on the platelet 
through P2Y1 and P2Y12 receptors [31]. ADP-induced shape change is mediated by 
P2Y1 receptors coupled to a G-protein and PLC –mediated intracellular calcium 
elevation [31,32]. The P2Y12 receptor is crucial for several platelet functions such as 
fibrinogen receptor activation [33], dense granule secretion [34], and ADP-mediated 
generation of TxA2 [35]. Activation of the P2Y12 receptor causes inhibition of 
adenylylcyclase and potentiates platelet activity by suppressing cyclic AMP formation 
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[36]. There are about 500-1000 binding sites for ADP on the platelet surface, one third 
are P2Y1 and two thirds P2Y12. This is about half of the number of receptors for potent 
agonists such as thrombin and TxA2 [37,38]. 
 
TxA2 acts on the specific G-protein coupled Thromboxane-Prostaglandin H2 (TP) 
receptor on the platelet surface causing PLC-signalling and platelet activation [31]. As 
noted above there are approximately twice as many TxA2 receptors as there are ADP 
receptors on the platelet. Following shape change the platelet GPIIb/IIIa receptors 
undergo activation elicited by a variety of agonists such as TxA2, ADP and thrombin. 
The receptors for these agonists act through G-proteins and “inside-out” signaling 
which initiates interactions with the cytoplasmic tail of the GPIIb/IIIa receptor. This 
causes a conformational change in the extracellular domain of the receptor from a low-
affinity to a high-affinity state [39] and allows binding of its principal ligand 
fibrinogen. This process is strongly dependent of elevation of cytosolic Ca2+ [39]. 
Binding of fibrinogen to the GPIIb/IIIa receptor leads to clustering and generation of 
“outside-in” in signalling which initiates several intraplatelet responses and promotes 
the assembly of a procoagulant surface for binding and steric arrangement of 
coagulation factors resulting in enhanced thrombin generation [40].   
 
Atherosclerotic plaque rupture exposes tissue factor (TF) to the circulation which 
activates the coagulation system leading to local thrombin generation. Thrombin is the 
most potent endogenous platelet activator and binds to specific thrombin receptors 
(PAR-1 and PAR 4) which activates platelets  and also results in positive feed-back via 
release of platelet activating factors like ADP and TxA2 [41-43]. Thrombin activates 
platelets at lower concentrations than those required to convert fibrinogen to fibrin and 
is very important in platelet recruitment during various thrombotic conditions [43,44]. 
 
 
Activated platelets shed microparticles from their membrane surfaces. Platelet-derived 
microparticles are highly procoagulant and catalyze the formation of thrombin around 
platelet microaggregates. Thrombin then converts fibrinogen to fibrin. The deposition 
of fibrin around platelet aggregates leads to consolidation of the thrombus [45]. 
Stability of the platelet aggregates and their rate of growth are important in determining 
whether a thrombus will be occlusive or will be dissolved by the blood flow and anti-
aggregatory compounds released from the vessel wall [15]. 
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Figure 1: Schematic representation of platelet activation in an atherosclerotic vessel. 
 
 
 
 
1.3.1 Thromboxane biosynthesis 
 
Upon platelet activation arachidonic acid (AA) is cleaved from the platelet membrane 
by phospholipase A2. AA is then oxygenated by Prostaglandin H synthase (PGH) into 
the endoperoxides prostaglandin G2 (PGG2) and PGH2. PGH-synthase has both 
cyclooxygenase (COX) and hydroperoxidase activity and is commonly termed COX 
[46]. COX exists in two isoforms of which COX-1 dominates in platelets [46]. PGH2 is 
further converted to TxA2 by a separate enzyme. TxA2 is the predominant product 
formed from AA in human platelets [47] and is a very potent vasoconstrictor and 
platelet agonist. However, TxA2 is also very unstable and is rapidly (within 
approximately 30 seconds) converted to TxB2, and then further metabolized to the 
stable metabolites 11-dehydro-TxB2 and 2,3-dinor-TxB2.  
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Figure 2: Biosynthesis of thromboxane and metabolites (modified from [48,49]).   
 
 
TxA2 is released episodically and has local effects. Its stable metabolites are excreted in 
urine 15-60 minutes after TxA2 biosynthesis in vivo. The capacity of human platelets to 
synthesize and release TxA2 when maximally stimulated ex vivo may be as much as 
5000 times higher than the basal TxA2 production [50,51]. Episodic increases in 2,3-
dinor-TxB2 and 11-dehydro-TXB 2 excretion have been detected in unstable angina 
[51,52,53]  and during percutaneous coronary intervention (PCI) [53]. 
 
Measurements of stable metabolites of TxB2 in urine are preferred when evaluating 
thromboxane formation in vivo.  80 % of 11-dehydro TxB2 excreted in urine is derived 
from platelets and 20 % from non-platelet sources [54,55]. 
 
 
1.4 PLATELETS AND ARTERIAL THROMBOSIS 
Platelets are key cellular components of an arterial thrombus [15]. The rupture of a 
plaque exposes a highly thrombogenic surface and this initiates platelet adhesion and 
aggregation followed by the formation of thrombin and vasoconstriction caused by 
substances released from or present on the aggregating platelets. A major plaque 
rupture with extensive exposure of collagen and substances in the atheromatous core  
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may lead to immediate formation of an occlusive thrombus with sudden cardiac death 
or myocardial infarction (MI). A minor disruption may cause a non-occlusive 
thrombosis and promote slow progression of atherosclerosis [14,56]. 
 
Atherosclerotic plaques are classified into eight morphologically distinct categories 
among which two are called vulnerable plaques. They are often small, but have a high 
lipid content [3,57] which makes them soft and vulnerable to disruption with ulceration 
and subsequent thrombosis [3,58]. During high shear flow the lipid-rich core, abundant 
in cholesteryl esters, display the highest trombogenicity in terms of platelet aggregating 
effects [59]. Lipid-lowering therapy may decrease this thrombogenicity [60].  
 
Platelet activation by shear stress seems to be important in arterial thrombosis [61]. 
Shear-induced platelet aggregation is enhanced in patients with acute MI [62,63]. 
Moake et al showed that platelet activation in response to disordered shear stress 
depends on the presence of plasma vWF and the functional platelet receptor complexes 
GPIb-IX-V and GPIIb/IIIa [64]. At low shear stress (<12 dynes/cm2) fibrinogen seems 
to be the bridging ligand but at higher shear levels plasma or subendothelial vWF is the 
ligand mediating aggregation and platelet adhesion [65]. In stenosed arterial vessels 
there is high shear stress and the ligand receptor affinity is changed so vWF binds to 
both GPIb and GPIIb/IIIa [66]. ADP and adrenaline act synergistically with shear force, 
and inhibition of ADP counteracts shear induced platelet activation [65]. COX-
inhibition by aspirin, on the other hand, has little effect on the initiation of aggregation 
by shear [63,65].  
 
Inflammation and thrombosis are interrelated pathophysiological processes that involve 
multicellular activities [67]. Activated platelets increase leukocyte adhesion to the 
endothelium and promote leukocyte activation through the deposition of chemokines 
on the endothelium [68].  
 
P-selectin is a membrane glycoprotein located in secretory α-granules in platelets and 
in endothelial cells [69]. P-selectin is rapidly redistributed to the plasma membrane 
upon cell activation [45]. P-selectin mediates interactions between platelets, leukocytes 
and endothelial cells [70] and stabilizes the initial interaction between GPIIb/IIIa and 
fibrinogen [71]. The main ligand for P-selectin is P-selectin Glycoprotein Ligand-1 
(PSGL-1), a disulfide-linked homodimer consisting of two polypeptide chains which is 
constitutively expressed on most leukocytes [72]. PSGL-1 is also found on platelets and 
can mediate platelet-endothelial interactions [73]. The expression of P-selectin is 
transient and it is endocytosed [74] or proteolytically shed from the platelet surface into 
plasma. Soluble P-selectin has been proposed to be a reliable marker for in vivo platelet 
activation [75,76]. In addition, P-selectin may be present on circulating platelet 
microparticles formed during platelet activation. 
 
CD40 ligand is a member of TNF-α family and is expressed by activated platelets [77] 
but was originally identified on activated T-cells. CD40L triggers an inflammatory 
response of endothelial cells [77], and stabilizes platelet rich thrombi. More than 95 % 
of the CD40L in whole blood is in platelets [78].  
 
Platelet-leukocyte aggregates (PLAs) are formed both in vivo and in vitro [79,80] and 
represent an interface between inflammatory, thrombogenic and atherogenic responses. 
Granulocytes, lymphocytes and monocytes can all form PLAs [79,81]. Several ligand-
receptor systems are involved in the formation of PLAs, including P-selectin and its 
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receptors. Increased PLA formation has been found in various diseases such as 
ischemic heart disease and diabetes mellitus [82-84].  
 
1.5 EFFECTS OF EXERCISE AND MENTAL STRESS 
Triggering of MI by heavy physical exertion and other various stressful conditions has 
been observed in several studies [13,56,85-87]. The risk is higher in sedentary 
individuals compared to individuals who are more physically active [88]. Physical 
exercise activates platelets more markedly than mental stress [89], but both mental and 
physical stress increase heart rate and blood pressure leading to increased myocardiac 
oxygen demand and may cause plaque rupture [56]. During stress platelets may be 
activated by the sympathetic nervous system, the hypothalamic-pituitary-adrenal axis 
and serotonergic pathways [10,13,87,90]. During physical exercise platelets may be 
activated by α2-adrenoreceptors that are stimulated by catecholamines [91,92]. A 
prothrombotic state with procoagulant activation (increased thrombin generation, 
platelet hyperreactivity, and increased activity of coagulation factors) outweighing the 
concomitant activation of fibrinolysis was observed during high intensity physical 
activity [93]. On the other hand platelet activation can be suppressed by moderate 
exercise [13,94]. Of note, regular exercise training [93] or preceding warm-up exercise 
[95] reduces the platelet responsiveness to exercise. Individuals performing regular 
exercise exhibit lower baseline coagulation activity compared to sedentary individuals 
and this, together with the reduction of platelet responsiveness, is thought to be one 
explanation for the finding that regular physical activity reduces atherothrombotic risk 
in the long run [93]. 
 
1.6 PLATELETS AND PREECLAMPSIA  
Normal pregnancy is associated with elevated levels of coagulation factors and 
increased platelet activation [96,97]. In patients with preeclampsia the hemostatic 
activity is further increased as reflected by increased thrombin generation, platelet 
activation and fibrin deposition in the placental vasculature [98]. Preeclampsia occurs 
in approximately 6 % of all pregnancies, and is one of the most common causes of 
mortality and morbidity in mothers and children in the Western world [25,99]. The 
disease process starts early in pregnancy but clinical signs of disease (high blood 
pressure and proteinuria) become apparent after 20 weeks of gestation [100]. 
Intrauterine growth retardation is often associated with preeclampsia, and is related to 
reduced uteroplacental blood flow [101,102]. The risk of developing preeclampsia is 
higher among women with diabetes mellitus and/or a previous history of preeclampsia, 
chronic hypertension, renal disease or multifetal gestation [103]. 
  
There is some evidence that platelets are involved in preeclampsia [104-106] and that 
the balance between the production of TxA2 from platelets and prostacyclin (PGI2) 
from endothelial cells is altered [107]. Endothelial dysfunction and a decrease in the 
prostacyclin/thromboxane ratio favours hypertension and may contribute to the 
reduction of uteroplacental blood flow seen in preeclampsia [108]. Patients with 
previous preeclampsia have an increased risk for developing hypertension and CVD 
[109] later in life, and large follow-up studies have found that there is an increased risk 
of cardiovascular death in women with previous preeclampsia, particularly when 
preterm delivery occurred [110,111].  
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1.7 ASSESSMENT OF PLATELET FUNCTION. 
Assessing platelet function and effects of antiplatelet therapy is complicated since no 
single laboratory test has been shown to be optimal in determining the effect of a drug 
[20,112]. Platelets can be activated by several different mechanisms, and they interact 
with each other and with vascular cells and leukocytes. The relationships between 
surrogate endpoints reflecting platelet function and clinical events are a critical issue. 
Assessments of platelet function entail many methodological issues. Precautions should 
be taken to minimize platelet activation in vitro. It is, e.g., important with careful blood 
sampling (i.e. free flow and no stasis) and immediate processing of the sample [113]. 
The performance of a platelet function test will depend on the skill of the user and there 
is, e.g., poor standardisation between laboratories regarding how light transmittance 
aggregometry (LTA) is performed [114]. Different tests for aspirin sensitivity showed 
poor agreement between them [115]. 
 
Anticoagulants must be used and they may artificially modify platelet responses [116]. 
Sodium citrate is the most commonly used anticoagulant which acts by chelating 
extracellular calcium. It has been shown that platelet secretion and aggregation 
stimulated by various agonists is enhanced in low calcium media [117-119]. Low 
extracellular calcium levels will result in enhanced generation of platelet-derived TxA2 
and this causes the “second wave” aggregation after exposure to ADP and adrenaline; 
this phenomenon does not occur at physiological Ca2+ concentrations (1-2 mM) [120]. 
The selective thrombin inhibitor hirudin appears to be the most suitable anticoagulant 
for studies of platelet aggregation with normal extracellular calcium concentrations 
[116]. 
 
Most studies of platelet function are performed in platelet rich plasma (PRP), which 
requires centrifugation of the blood. This procedure may remove the largest and most 
active platelets but also red and white cells which are known to influence platelet 
behaviour [121]. In addition, in PRP platelet-platelet contact is facilitated which may 
increase platelet responsiveness in a non-physiological manner. A more physiological 
approach is therefore to study the platelets in whole blood [122].  
 
1.7.1 Platelet aggregation 
The most common in vitro technique is LTA, which is sometimes called Born 
aggregometry as it was originally described in the early 1960´s by G Born [123].This 
method measures changes in light transmittance in PRP following platelet aggregation. 
Using this method dose-response curves for aggregation induced by different agonists 
and effects of drugs can easily be investigated.   
 
Platelet aggregation can also be measured in whole blood by impedance platelet 
aggregometry [124].  This method measures the deposition of platelets and platelet 
aggregates on electrodes in whole blood, i.e. in the presence of other blood cells, and 
may thus be considered to be more “physiological” than LTA. 
 
Another method that assesses platelet aggregation in whole blood is filtragometry ex 
vivo, as described by Hornstra [125]. Filtragometry measures platelet aggregate 
formation (aggregability) in whole blood drawn directly from an antecubital vein and in 
the presence of physiological calcium levels. Our group has used this technique to 
study dynamic changes of platelet function in vivo and effects of various kinds of stress 
and stress hormones [12,89-92]. 
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1.7.2 Flow cytometry 
Flow cytometry is a powerful technique for platelet studies which requires only small 
amounts of blood and allows platelet activation to be studied in a physiological milieu. 
Flow cytometry detects individual cells/particles or cellular conjugates that pass a laser 
beam during a continuous flow of cells. To detect specific alterations on the surface of 
or in activated platelets fluorescently labelled monoclonal antibodies or fluorescent 
dyes are used. Fluorescence and scatter light signals are recorded by specific 
photodiodes. Mean fluorescence intensity (MFI) or % positive cells can be determined 
to measure the expression of antigen following binding of an antibody. The cell size 
and granularity are proportional to forward and side scatter of light, respectively. 
 
1.7.3 Analysis of 11-dehydro-TxB2 in urine and plasma 
11-dehydro-TxB2 is the major metabolite of TxA2 in man [126,127]. The urinary 
excretion of 11-dehydro-TxB 2 appears to reflect phasic thromboxane generation and 
platelet activation in humans [126,128]. It has a longer half-life in plasma than 2,3-
dinor-TxB2 (45 vs 15 minutes) [49]. With regard to their urinary excretions, the 
fractional elimination of 11-dehydro TxB2 was independent of the rate of TxB2 infusion 
whereas the elimination of 2,3 dinor-TxB2 was nonlinearly related to the dose of TxB2 
[128]. Efficient purification of human urine is needed when analyzing prostanoids by 
enzyme immunoassay (EIA) due to the large amounts of unrelated material in these 
fluids that interfere with the ligand-antibody binding in the assay. Even the “gold 
standard” method for analysis of 11-dehydro TxB2, i.e. gas-chromatography-mass 
spectrometry (GC-MS), requires a good extraction procedure for reliable measurements 
[129].  
 
1.8 ANTIPLATELET TREATMENT  
1.8.1 Aspirin 
Aspirin is an extensively evaluated antiplatelet drug which reduces cardiovascular 
events in various clinical settings by 19-32 % depending on the dosage [16]; in unstable 
coronary artery disease the protective effect of aspirin treatment is even greater [130].  
Aspirin has also been used to prevent the development of preeclampsia. In a Cochrane 
review a 17 % reduction of the risk of developing preeclampsia by antiplatelet 
treatment was reported [131].  
 
1.8.1.1 Mechanism of action 
The antiplatelet effects of aspirin are considered to be mediated mainly by irreversible 
inhibition of platelet COX which blocks the synthesis of the strong platelet agonist 
TxA2 [132]. As mentioned above COX occurs in two isoforms, COX-1 and COX-2, of 
which platelets under normal conditions mainly contain COX-1. Aspirin is 50-100 fold 
more potent in inhibiting platelet COX-1 than COX-2 [133]. Platelet COX-1 activity is 
irreversibly inhibited by acetylation of a serine residue (ser529), which prevents access 
of the substrate AA to the catalytic site of the enzyme [134], thus inhibiting the 
cyclooxygenase activity of the enzyme. The inhibitory effect lasts the life span of the 
platelet [135] because mature platelets are anucleate and therefore not able to 
regenerate COX. The effect of repeated daily low doses of aspirin is cumulative and a 
steady state with regard to platelet COX inhibition is reached within approximately 7 
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days [136]. After a single high dose of aspirin, platelet COX activity recovers by 
approximately 10 % per day as a function of platelet turn-over [137].The recovery rate 
may, however, vary both within and between patients.  
 
According to older studies, the relationship between thromboxane formation and 
platelet aggregation is non-linear and as little as < 5 % residual capacity to generate 
TxA2 is enough to fully sustain thromboxane dependent platelet aggregation [138,139]. 
However, this concept has recently been challenged as Armstrong found a linear 
relationship between the degree of inhibition of platelet TxA2 generation and TxA2 
mediated aggregation [140]. 
 
A high platelet turnover is associated with a larger population of circulating immature 
reticulated platelets with a higher granule content and residual megacaryocyte-derived 
mRNA. Reticulated platelets have a greater prothrombotic potential than smaller 
platelets [141]. In situations with high platelet turn-over newly formed platelets 
replenish platelet COX-1 more rapidly, thus allowing faster restoration of thromboxane 
synthesis by platelets not previously exposed to aspirin [142]. Recovery of serum TxB2 
was, e.g., found already 4 hours after ingestion of 650 mg aspirin in healthy volunteers 
[139]. COX-2 can be detected in patients with high platelet turnover and many 
circulating reticulated platelets, which might to some degree, explain aspirin-insensitive 
TxA2 synthesis [143].  
 
1.8.1.2 Pharmacokinetics 
Aspirin is rapidly absorbed and inhibition of platelet function can be seen within 60 
minutes. The plasma half-life of acetylsalicylic acid is 20 minutes, whereas that of 
salicylate is considerably longer [144]. At low dosages, first pass hepatic metabolism of 
aspirin limits the systemic exposure of the patients to COX inhibition and preserves the 
vasodilating and antiplatelet effects of endothelial PGI2 [145].Thus, low-dose aspirin 
acts presystemically in the portal circulation with regard to platelet inhibition [55,146]. 
 
1.8.1.3 Effective dosage and clinical efficacy of aspirin 
Aspirin is an effective antithrombotic agent when used in doses ranging between 30-
1500 mg/day. 75-150 mg daily appears to be the most effective dose [16]. There is no 
evidence that these low doses are less effective than high doses (i.e., 650-1500 mg/day) 
with respect to platelet inhibition, but lower doses produce fewer gastrointestinal side 
effects, and low doses may also have greater “antithrombotic” effects as the COX-2 
mediated synthesis of PGI2 in vascular endothelial cells is less affected [16,46,55].  
 
Several studies have shown that aspirin effects are limited and that some patients at risk 
may not benefit from aspirin protection against cardiovascular events. This 
phenomenon is often named “aspirin resistance” and should not be confused with 
“treatment failure” which may be related to other disease mechanisms and poor 
compliance rather than “true” or “biochemical” aspirin resistance [19,22,147]. Aspirin 
has variable platelet inhibitory effects when assessed by different methods. Using 6 
different tests 2.8-59.5 % of 201 patients in a study were judged not to have optimal 
antiplatelet effects during aspirin treatment [115]. The prevalence of “aspirin 
resistance” was highest using the Platelet Function Analyser PFA-100, a point-of-care 
method that activates platelets by shear stress and agonists (epinephrine and collagen) 
and lowest using LTA with AA (1.6 mM) as agonist.  
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With the use of “COX-specific” methods such as LTA+AA and measurements of 
platelet dependent thromboxane formation, the incidence of true “aspirin resistance” in 
compliant patients is probably as low as < 1 % [22,54]. Non-specific methods such as 
collagen- or ADP-induced platelet aggregation in PRP or urinary thromboxane 
metabolite excretion yield much higher frequencies of “aspirin resistance” 
[22,54,115,147,148]. In meta-analyses, however, patients with signs of “aspirin-
resistance” had an approximately four-fold increased risk of developing cardiovascular 
events regardless of the specificity of the assay method used to assess platelet inhibition 
by aspirin [148,149]. Thus, both methods that selectively measure platelet COX 
inhibition and methods that assess platelet function more globally carry prognostic 
information, and which method(s) that may be suitable for clinical use by point-of-care 
testing is still debatable. 
 
Poor compliance is a matter of great concern when responses to drug treatment are 
evaluated, and aspirin treatment is no exception. It is possible to assess aspirin 
compliance, e.g. through various biochemical assessments, but this is missing in the 
majority of studies assessing aspirin effects on platelet function [137]. In addition to 
compliance, the importance of hyperreactive platelets, and the time between 
measurements and the last intake of aspirin (which is seldom noted) have to be taken 
into consideration when evaluating “aspirin resistance” [19] . 
 
Healthy women exhibit greater platelet aggregation in response to different agonists 
and have a greater urinary TxB2 excretion compared to men before aspirin treatment 
[150]. The degree of inhibition by aspirin was significantly less in women when 
assessed using collagen and ADP. With a cutoff of >70 % inhibition of collagen-
induced platelet aggregation, 30 % of women and 16 % of men were “aspirin resistant” 
[150]. 
 
As mentioned above, aspirin has also been used to prevent the development of 
preeclampsia. However, in the largest randomized controlled study of aspirin 
performed so far, the CLASP study, preventive treatment with aspirin 60 mg daily 
(usually after 12 weeks of pregnancy) compared to placebo only tended to reduce the 
incidence of proteinuric preeclampsia by 12 % (not significant) [25]. Reasons behind 
this relatively poor efficacy might be that the dosage of aspirin used was too low and/or 
that the treatment was initiated too late.  
 
1.8.1.4 Other aspirin effects 
There is some evidence that mechanisms unrelated to its ability to inactivate platelet 
COX-1 may contribute to the antithrombotic effects of aspirin. For example, inhibition 
of thrombin generation [151-153] and increased fibrin network permeability [154-156] 
which facilitates fibrinolysis [157] may contribute.  Aspirin also decreased the 
maximum rate of FXIII cleavage and delayed FXIII activation by thrombin in a model 
of microvascular injury [158]. Reduced TF expression in human atherosclerotic plaques 
has been seen after aspirin treatment in smokers [159]. An interesting finding is that 
inhibition of thrombin generation by aspirin 75 mg/day was seen only in patients with 
total plasma cholesterol levels below 5,2 mmol/L [158].   
 
1.8.2 Clopidogrel 
 The clinical efficacy of clopidogrel treatment is very well documented 
[17,20,160,161]. Today, treatment with thienopyridines including clopidogrel in  
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combination with aspirin is the “gold standard” for attenuation of platelet activation 
during acute coronary syndromes and in patients undergoing coronary stenting [6]. The 
CAPRIE study [162] showed a slightly greater reduction of vascular events with 
clopidogrel (75 mg/day) compared to aspirin (325 mg/day) in high risk patients with 
atherosclerosis. However, no comparison with the optimal dose of aspirin 75-150 
mg/day [16] has ever been performed in a large scale setting. Combined therapy with 
aspirin and clopidogrel is indicated during and after an acute coronary syndrome and in 
the setting of coronary artery stenting following PCI. The duration of dual antiplatelet 
treatment is a matter of debate but it should only be given during limited periods of 
time due to the time course for the risk-benefit ratio [160,163]. The CHARISMA study 
randomized patients at high cardiovascular risk with pre-existing cardiovascular disease 
or risk factors to combined treatment with clopidogrel and aspirin or aspirin alone; the 
effects of combined treatment were less marked than in the CURE study and a  
significant increase of bleeding was seen [17,164]. 
 
 
1.8.2.1 Mechanism of action 
Treatment with clopidogrel selectively and irreversibly inhibits the low affinity P2Y12 
receptor on platelets [165,166], resulting in non-competitive inhibition of ADP-induced 
platelet fibrinogen binding and platelet aggregation The active metabolite  of 
clopidogrel is highly labile and reacts as a thiol reagent with the ADP-receptor thus 
causing irreversible alterations of the receptor [167]. This is consistent with time-
dependent cumulative inhibition of ADP-induced platelet aggregation upon repeated 
daily dosing without or with a low loading dose, and there is a slow recovery of platelet 
function after drug withdrawal [166]. Clopidogrel does not affect the P2Y1 or P2X1 
purinergic receptors on the platelet surface. Clopidogrel treatment reduces the stability 
of platelet aggregates and may also inhibit platelet aggregation induced by low 
concentrations of collagen or thrombin. The latter most likely reflects blockade of the 
amplification of platelet responses to other agonists mediated by ADP released from 
activated platelets [137]. Clopidogrel may also attenuate PLA formation and reduce the 
plasma concentrations of CRP, soluble P-selectin and CD40L [168-170]. 
 
1.8.2.2 Pharmacology of clopidogrel 
Clopidogrel is a prodrug that requires metabolism by the hepatic cytochrome P450 
enzyme system in order to form the active metabolite and exhibit antiaggregatory 
effects. Clopidogrel is metabolized in two steps, first an oxidation to 2-oxoclopidogrel 
and then hydrolysis to the active metabolite [171-173]. SR26334, an inactive 
carboxylic acid derivative, is the principal circulating metabolite [174]. The plasma 
elimination half-life of the inactive metabolite is approximately 8 hours (h) [137], 
whereas the half-life of the active metabolite is only approximately 0,7 h [175]. The 
active metabolite of clopidogrel does not influence ADP-induced shape change [165]. 
P2Y1- and P2Y12 receptors act synergistically through different signalling pathways and 
therefore there is a limited effect of inhibiting only the P2Y12 receptor by clopidogrel 
treatment [176].  
 
 
1.8.2.3 Effective dosage and clinical efficacy of clopidogrel 
There is a relationship between clopidogrel non-responsiveness and/or high on-
treatment platelet reactivity and adverse clinical ischemic events [20,21]. In patients 
undergoing stenting for acute MI there was a 40 % increased 6-month risk of suffering 
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 a recurrent cardiovascular event among patients in the highest quartile of ADP-induced 
aggregation during clopidogrel treatment, i.e. loading dose 300 mg and maintenance 
dose of 75 mg daily [177]. Increasing the dose of clopidogrel produces increased 
inhibition of ADP-induced platelet aggregation up to a plateau of inhibition of 50-60%, 
on average [137]. The initially used loading dose of 300 mg clopidogrel [163,177,178] 
has been replaced by 600 mg [179] which, when followed by 75 mg daily, produces 
rapid and sustained platelet inhibition. However, there are numerous reports of 
response variability and non-responsiveness to clopidogrel therapy [180,181]. It has 
been shown that non-responsiveness is dependent on the dose.  Thus, a 600 mg loading 
dose reduced clopidogrel non-responsiveness to 8 % compared to 28-32 % after a 300 
mg loading dose in patients undergoing elective PCI [182]. 
 
LTA is the most commonly used method to evaluate clopidogrel responsiveness and 
residual post-treatment P2Y12 activity through measurements of ADP-induced platelet 
aggregation [180]. However, ADP also binds to P2Y1 receptors and the effects of ADP 
on platelet function also reflect unblocked effect on ADP signalling through P2Y1 
[176]. Measurements of the vasodilator-stimulated phosphoprotein (VASP) 
phosphorylation by flow cytometry are specific with regard to signalling through P2Y12 
receptors and therefore more specific for the inhibitory effects of clopidogrel [180,183]. 
Approximately 20% of patients undergoing PCI were judged to be clopidogrel non-
responders by various laboratory methods, and they exhibited an increased risk of 
worsened cardiovascular outcomes [184].  However measurement of responsiveness 
(absolute or relative changes in platelet aggregation compared to before treatment) may 
not be the optimal method to find patients at high risk due to the interindividual 
variability in baseline ADP-induced platelet aggregation [21] .The absolute level of 
platelet reactivity during treatment is proposed to be a better measure of thrombotic risk 
[21] . 
 
The mechanisms behind clopidogrel response variability and resistance are 
incompletely defined. Poor patient compliance is an important consideration and 
probably an underestimated cause of inadequate responses to clopidogrel [185]. 
Differences in intestinal absorption, differences in the conversion to the active 
metabolite by hepatic cytochrome P450, and platelet receptor polymorphism have been 
suggested to contribute to the response variability [175,185,186]. For example, 
CYP2C19, which is involved in the metabolism of clopidogrel to the intermediate 
metabolite, exhibits polymorphisms [180,187] and this and other isoenzymes may be a 
target for drug-drug interactions. There are several commonly prescribed competitive 
substrate drugs for CYP2C19, among which omeprazol and esomeprazole (PPI) have 
received most attention. Pharmacodynamic and pharmacokinetics studies suggest that 
concomitant use of clopidogrel and PPI reduces antiplatelet effects of clopidogrel using 
various platelet assays but effects on cardiovascular outcomes have not been 
established [188]. An interaction between CYP3A4 metabolized statins and clopidogrel 
has been proposed [189,190] but Malmström et al were unable to verify any importance 
of such a drug-interaction [191]. In summary, there is no consistent evidence that 
clopidogrel-drug interactions are of clinical importance [192]. 
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2 AIMS OF THE STUDY     
• To develop and optimize an enzyme immunoassay for analysis of 11-dehydro-
TxB2 in urine for measurements of thromboxane generation in vivo. 
• To evaluate the dose- and time-dependence of the platelet inhibition effects of 
aspirin in order to better understand the potentials and limitations of treatment 
with this drug.  
• To investigate the production of thromboxane in normal pregnancy and in 
pregnancy complicated by preeclampsia, as well as effects of aspirin treatment. 
• To study the effect of clopidogrel treatment during platelet activation in vivo by 
exercise, in healthy volunteers and in aspirin treated patients with stable 
coronary artery disease (CAD).  
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3 PATIENTS AND METHODS 
 
3.1 STUDY POPULATION 
Urine samples were obtained from thirteen healthy volunteers and twenty-eight  
patients with CAD for the methodological work in study I. Urinary samples were also 
obtained from eight healthy subjects who were free from treatment with aspirin and 
other platelet inhibiting drugs before, and 12 hours after the ingestion of 500 mg aspirin 
in study I.  
 
Thirty healthy male volunteers with easily accessible antecubital veins between 21-39 
years of age were recruited among medical students for studies II and IV. One 
volunteer nearly fainted after exercise on the second occasion in paper IV. After the 
experiment he reported lack of sleep and malaise prior to this vaso-vagal episode and 
we therefore excluded him from the study. 
 
Thirty-one male patients with stable angina pectoris, a pathological exercise stress test 
and CAD documented by coronary angiography, participated in study V. All patients 
were on the waiting list for elective coronary artery by pass grafting (CABG) at the 
Karolinska Hospital.   
 
Twenty-eight pregnant women at high risk for developing preeclampsia (i.e., with a 
history of previous preeclampsia and/or intrauterine growth retardation, SLE or 
hypertension) and twenty-two healthy normotensive pregnant women participated in 
study III. 
 
3.2 STUDY DESIGNS 
 
3.2.1 Study II 
The study was an open study with measurements at baseline (untreated) and during 
treatment with three different dosages of aspirin (fig 3). Measurements were performed 
at baseline and after aspirin treatment with 37.5 mg/day for 10 days and 320 mg/day for 
7 days with a wash-out period of two weeks between low- and high-dose aspirin. 
Finally, they took a single dose of 640 mg aspirin 2 h after the last 320 mg dose. Blood 
sampling was performed before, 1.5 – 2 h, 6 h and 24 h after 37.5 mg, before and 1.5-2 
h after 320 mg and finally 4 and 24 h after the last very high dose of aspirin (fig 3). 
Each subject brought his morning urine to the laboratory before the first blood 
sampling and when he returned the next day for 24 h sampling. Urine samples were 
also collected at 1 PM on days of experiment.  
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Figure 3: Design of study II  
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3.2.2 Study III 
Aspirin treatment of patients with high risk of suffering preeclampsia commenced 
between gestational weeks 6-13 and was supposed to be stopped 2 weeks before 
delivery. Urine samples were collected before aspirin treatment, after two weeks of 
aspirin treatment, in pregnancy week 28-32, and 3-9 days post partum. Urine samples 
from healthy pregnant women (controls) were collected on four occasions: before 
gestational week 13, between gestational week 32-36, and 3-9 days and 3 months after 
delivery. 
 
3.2.3 Study IV  
The study was a randomized, open cross-over study comparing the effect of exercise 
without and with pretreatment with clopidogrel 75 mg/day for 7 days in healthy male 
volunteers. The volunteers sampled urine from the preceding night upon awakening. 
Another urine sample was collected 1 hour after termination of exercise. Blood samples 
and filtragometry readings for measurement of platelet aggregability were performed 
before and after an exercise test which was terminated upon exhaustion. 
 
3.2.4 Study V 
The study was randomized, double-blind and placebo-controlled. All patients had 
ongoing treatment with aspirin (75-160 mg daily) during the entire study. After the first 
study visit the patients were randomized to treatment with either clopidogrel 75 mg or 
matching placebo once daily. The patients visited the laboratory before and after 14 
days of study drug treatment. Blood samples were taken before and immediately after 
exercise. The exercise test was symptom limited and terminated upon severe chest pain, 
shortness of breath or fatigue, or other signs of severe myocardial ischemia 
(Electrocardiographic recordings (ECG) changes), falling blood pressure or severe 
arrhythmias). Continuous ambulatory ECG monitoring (48 h) was performed at 
inclusion and after two weeks of study drug treatment in order to evaluate treatment 
effects on ambulatory myocardial ischemia.  
 
3.3 BLOOD SAMPLING 
All subjects had antecubital veins allowing technically good sampling. Blood sampling 
for baseline or pre-exercise measurements was performed after 30 minutes of rest in the 
supine position. Upon termination of exercise blood sampling was repeated 
immediately.  Healthy volunteers and patients were instructed to refrain from caffeine 
and tobacco ≥12 h before experiments. They were also instructed not to take any 
platelet inhibiting drugs during 14 days preceding sampling. In study V all patients 
received chronic aspirin treatment 75-160 mg once daily (see above). 
 
3.3.1 Anticoagulants 
We used hirudinized blood in study II to avoid artifactual enhancement of the TxA2-
dependence of platelet aggregation (and thus the efficacy of aspirin) which is seen 
when citrate is used as anticoagulant and extracellular calcium levels are low 
[116,118,120].   
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3.4 PLATELET FUNCTION TESTS 
 
3.4.1 Bleeding time 
Standardized transverse incisions were made on the lateral volar side of the forearm, at 
a constant venous pressure of 40 mmHg, using a disposable device (Surgicutt II, Ortho 
Diagnostics, Raritan, NJ, USA). Repeated incisions were made 10 mm distally to the 
previous one to avoid influences of previous measurements on the same occasion. Total 
bleeding time was measured by collecting blood on filter papers at 15 s intervals 
according to a previously described technique [193,194]. In our laboratory the intra-
individual coefficient of variation for total bleeding time is 14 % [194].  
 
 
3.4.2 Filtragometry 
Filtragometry monitors platelet aggregate formation in whole blood ex vivo [125]. 
Blood is drawn continuously from an antecubital vein and anticoagulated by heparin 
before passing through a nickel filter with a pore size of 20µm. The apparatus may 
contribute to platelet aggregate formation (via contact with the siliconized tubing 
system and/or through shear forces when blood passes the filter) but this contribution is 
identical in all measurements. The time in seconds (aggregation time, tA) taken to reach 
the predetermined degree of filter occlusion is inversely related to platelet aggregability 
in vivo [12,125,195]. A rapid filter occlusion with a low tA value indicates high platelet 
aggregability. The coefficient of variation for between-day variability of two resting 
measurements is 7.8 % for log tA [196]. 
 
3.4.3 Whole blood aggregometry 
Platelet aggregation in whole-blood was studied in papers II and V using a four channel  
impedance aggregometer (Chrono-log model 570-VS four Sample; Chronolog Corp, 
Haverton PA USA). The blood was anticoagulated with recombinant hirudin (in paper 
II) or citrate (in paper V) and diluted 1:1 with physiological saline. Samples were 
preincubated at 37° C for 5 minutes, after which agonists were added. Agonists used 
were collagen type 1 (Horm Nycomed Arzneimittel, Munich, Germany) at final 
concentrations of 1, 3 and 5 µg/mL (paper II) or 1 and 5 µg/mL (paper V), and AA 
dissolved in ethanol (Sigma Chemical Co, St Louis, MO, USA) at final concentrations 
of 0.2, 0.5 and 1 mM (paper II) and 0.5 mM (paper V). The amplitude of aggregation 
was measured after 8 minutes. 
 
3.4.4 Aggregometry in platelet rich plasma (PRP) 
A four-channel platelet aggregation profiler (PAP-4, Bio-Data Corporation, Hatboro, 
PA, USA) was used in paper II to study platelet aggregation in PRP. ADP was diluted 
in Tris buffer and the EC50 for ADP (i.e., the concentration required for half-maximal 
aggregation) was determined by a dose-response procedure in which the extent of 
aggregation after 4 minutes was measured [9]. Platelet COX inhibiting effects of 
aspirin treatment were determined as the ability of AA (final concentrations 0.5 and 1 
mM) to induce aggregation in PRP.   
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3.4.5 Flow cytometric analysis 
Five µL citrated whole blood was added to 45 µL of Hepes buffered saline (to 
minimize in vitro aggregate formation) within 3 min of blood sampling. The tubes 
contained appropriately diluted antibodies and agonists for detection of platelet P-
selectin expression, leukocyte CD11b expression or platelet-leukocyte conjugates. 
After incubation for 20 minutes samples were further diluted and fixed with 0.5 % 
formaldehyde in saline before analysis in an EPICS XL-MCL flow cytometer (Coulter 
Corp, Hialeah FL).  Flow cytometric analyses in papers IV and V were performed as 
described previously [195,197-199]. 
  
 
 
3.4.5.1 Single platelet analysis 
Platelets were identified with the FITC-conjugated anti-CD42a (GPIX) monoclonal 
antibody Beb1 (Becton Dickinson, San Jose, CA, USA). Platelet P-selectin expression 
was identified with the RPE- (R-phycoerythrin) conjugated anti-P-selectin monoclonal 
antibody AC1.2 (Becton Dickinson). Platelets were first gated according to their 
characteristic light scattering signals, and then confirmed by FITC-CD42a staining 
(>99% positive). The gated cells (>99% platelets) were subsequently subjected to 
single colour analysis of RPE-CD62P fluorescence to obtain the percentage of P-
selectin positive cells in the platelet population [195,197]. Agonists used for in vitro 
stimulation were ADP and human α-thrombin (fibrinogen polymerisation was 
prevented by adding the peptide GPRP when thrombin was used). 
 
3.4.5.2 Platelet leukocyte aggregates (PLA) 
Leukocytes were identified with the RPE-conjugated anti-CD45 monoclonal antibody 
J33 (Immunotech, Marseille, France), and gated as lymphocytes, monocytes and 
neutrophils according to CD45 expression and light scattering characteristics [198].  
Total leukocytes and the different subsets were then subjected to two colour analysis 
(RPE-CD45 vs FITC-CD42a) to discriminate platelet-free and platelet-coupled 
leukocytes. Platelet leukocyte aggregates are reported as percentages and counts of 
platelet-bound total leukocytes (PLA), neutrophils, monocytes and lymphocytes.  
 
3.4.5.3 Leukocyte CD11b expression 
Leukocyte CD11b expression was analysed as a marker of leukocyte activation. Mean 
fluorescence intensities of FITC-CD11b staining among total leukocytes, granulocytes, 
lymphocytes and monocytes were reported [199]. Agonists used for in vitro stimulation 
were ADP and fMLP (N-formyl-methionyl-leucyl-phenylalanine). 
 
3.4.6 Platelet function analyser (PFA-100) 
The PFA-100 analyzer (Dade Behring, Germany) was used for measurements of 
platelet-related primary haemostasis capacity in citrate-anticoagulated whole blood 
under high shear conditions [200]. Closure time (CT) is the time needed to form a 
platelet plug occluding a small aperture in a collagen/epinephrine or collagen/ADP 
coated membrane. In the present project only the aspirin sensitive collagen/epinephrine 
coated membranes were used. 
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3.4.7 Thromboxane related measurements 
 
Urinary 11-dehydro-TxB2 was determined by EIA using commercially available 
reagents (Cayman Chemicals, Ann Arbor MI USA) and a sample work-up procedure 
described and validated in paper I. Importantly, 11-dehydro-TxB2 occurs in two forms 
in a pH-dependent equilibrium. At basic pH it is converted to an open ring structure 
with a carboxyl group at C-11 which is a strong antigenic determinant influencing the 
affinity and specificity of antisera [201].  Thus, two ml of centrifuged urine was diluted 
1:2 with 63 mM ammonium bicarbonate buffer pH 8.6 and was incubated for 3 hours to 
convert 11-dehydro-TxB2 to its open ring form before extraction with Bond-Elute 
Certify-II columns (Varian, Harbour City, CA, USA). The analyte was eluted with 2% 
formic acid in ethanol. The eluate was evaporated in a vacuum centrifuge, resuspended 
in buffer (pH 8.6), and incubated for 6 hours before analysis. This method was also 
adapted for measurements in plasma in paper IV. 
 
Serum TxB2 was determined using commercially available kits for measurements of 
TxB2 (Cayman Chemicals). Serum was produced by incubation of non-anticoagulated 
whole blood samples at 37oC for 1 hour, followed by centrifugation. Sample 
preparation and analysis were according to instructions from the manufacturer. 
 
3.4.8 Urinary 2,3 dinor 6-keto prostaglandin F1α 
Analysis of the 2, 3-dinor-6-keto-prostaglandin F1α metabolite of prostacyclin (PGI-M) 
in urine seems to be the most accurate method for assessment of systemic (extrarenal) 
prostacyclin biosynthesis [202]. Urinary PGI-M was determined in paper II by LC/MS-
MS after solid phase extraction, liquid-liquid extraction and derivatization with 
methoxyamine (Rooney C, unpublished). 
 
3.4.9 Soluble markers in plasma in paper IV and V 
Thrombin generation was measured as prothrombin fragment 1+2 in plasma prepared 
from whole blood samples anticoagulated with 3.8 % citrate (Enzygnost F1+2; Behring 
Diagnostics, Marburg, Germany). 
 
Blood samples for analyses of vWF, Il-6 and elastase in plasma were anticoagulated 
with 3.8 % citrate and centrifuged 10 min at 1400 x g at 4 oC. EIAs were used to 
determine vWF (Asserachrom, Diagnostica Stago, France), Il-6 (R&D Systems, 
Abingdon, UK) and elastase (DPC Biermann GmbH, Bad Nauheim, Germany). 
Soluble CD40L was determined by EIA (kit) in serum in study V and in EDTA plasma 
in study IV. Serum C-reactive protein (CRP) was determined by a high-sensitive 
nephelometric assay (Cardiophase hsCRP, Dade Behring). 
 
3.5 STATISTICAL ANALYSIS 
Descriptive statistics are presented as mean values ± SEM. Normally distributed 
variables were compared with paired t-tests. Effects of treatment were analyzed by 2-
factor repeated measures ANOVA for overall effects. Skewed data were log 
transformed before analysis by ANOVA (papers IV and V). In paper I bleeding time 
data were compared with the Wilcoxon test and with Spearman’s rank correlation. 
Statistica version 5.5 was used for calculations; p<0.05 was considered significant. 
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3.6 ETHICAL CONSIDERATIONS 
Studies II and III were approved by the local Ethics Committee of the Karolinska 
Hospital. Studies IV and V were approved by the Ethics Committee of the Karolinska 
Institute and by the Swedish Medical Products Agency. Informed consent was obtained 
from all subjects. The urine samples used in study I were unidentified, and a gift from 
our co-author, Professor Desmond Fitzgerald, Dublin, for methodological studies and 
had been obtained with permissions and consent according to Irish regulations. 
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4 RESULTS AND DISCUSSION 
 
4.1 OPTIMIZATION OF AN ENZYME IMMUNOASSAY FOR 11-DEHYDRO-
THROMBOXANE B2 IN URINE: COMPARISON WITH GC-MS.    
(PAPER I) 
 
In this study we described an improved immunoassay procedure for 11-dehydro-TxB2 
in urine based on a one-step solid phase extraction using Bond-Elut Certify-II columns 
followed by EIA using commercially available reagents. A key feature of the assay was 
to keep 11-dehydro-TxB2 in its open ring form with a carboxyl group at C-11 (a strong 
antigenic determinant) during the entire assay procedure by equilibrating at pH 8.6. 
This improved the performances of both the sample work-up and analysis steps. The 
detection limit of the assay (conservatively defined as the IC80) decreased from 10±6 
pg/mL with EIA-buffer pH 7.4, to 6±2 pg/mL with an EIA-Ambic buffer at pH 8.6. 
 
Efficient purification of human urine is needed when analyzing prostanoids by EIA due 
to the large amounts of unrelated material that may interfere with the ligand-antibody 
binding in the assay. The Bond-Elut Certify-II columns contain mixed phase material 
with lipophilic and anion exchange parts. The open ring form of 11-dehydro-TXB2 is 
retained in the column by ionic binding during washing with methanol. Elution of 11-
dehydro-TxB2 from the Certify-II columns was accomplished using formic acid in 
methanol as ion-changer. This extraction procedure resulted in a recovery of 83 % 
(95% confidence interval 74-92 %) in 11 urine samples spiked with 500 pg/mL 11- 
dehydro-TxB2.  
 
Intra- and interassay coefficients of variation of the final assay were 3 and 13.8 %, 
respectively. Comparison with GC-MS showed excellent agreement between the two 
methods (r2=0.94, p<0.0001). Samples with high levels (>10 000 pg/mL) were 
overestimated by EIA. This is to be expected as specificity problems with an 
immunoassay procedure will increase when the amounts of prostanoids in urine are 
high. Overestimation by the EIA method at the highest levels may be due to the 
presence of other thromboxane metabolites with similar structural features (e.g. 11-
dehydro-2,3 dinor-TxB2) which is also abundant in urine and can be expected to behave 
similarly as 11-dehydro-TxB2 in the extraction procedure. The administration of 500 
mg aspirin decreased the urinary excretion of 11-dehydro-TxB2 by 77±13 % in healthy 
volunteers, in agreement with prior results using GC-MS [202]. GC-MS methods 
incorporating an ideal internal standard are the most accurate when analysing 11-
dehydro TxB2 [129,203] but may be unsuitable for analysis of large numbers of 
samples due to limited analysis capacity and high costs.  
 
In summary, we described a simple work-up procedure which, when combined with a 
modified commercially available EIA for 11-dehydro-TxB2 , provides results that agree 
well with those obtained by the gold standard method, GC-MS. Raising the pH to 8.6 
results in dependable analyte behaviour during solid phase extraction, and also 
increases the sensitivity of the assay. 
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Figure 4: Comparison of concentrations of 11-dehydro-TxB2 obtained by GC-MS and 
the modified EIA described presently in 28 samples with a wide range of 11-dehydro-
TxB2 concentrations. The line of identity is indicated. Equations and correlation 
coeffients (r2) are indicated for all samples and for samples with <10 000 pg/mL 11-
dehydro-TxB2 by GC-MS.  
 
 
4.2 DOSE- AND TIME-DEPENDENT ANTIPLATELET EFFECTS OF 
ASPIRIN. (PAPER II) 
Fifteen male healthy volunteers ingested different doses of aspirin (37.5 mg during 2 
weeks followed by 320 mg during 7 days, and, finally, a single dose of 640 mg 2 h after 
the last 320 mg dose, i.e., totally 960 mg on the last day) in an open cross-over study to 
evaluate the dose- and time-dependence of antiplatelets effects of aspirin. 
 
Platelet COX-inhibition was nearly complete already with 37.5 mg aspirin daily as 
evidenced by >98 % suppression of serum TxB2 and almost abolished AA induced 
aggregation in PRP 2-6 h after dosing. The platelet sensitivity to ADP decreased after 
37.5 mg aspirin as the EC50 for ADP increased by 65±11 % (p<0.01) but this effect was 
less pronounced (not significant) after higher doses of aspirin. 
 
Bleeding time was similarly prolonged by all doses of aspirin. Eight of the 15 
investigated subjects had <60% increments of bleeding time after 37.5 mg aspirin and 
similarly low increments after 320 mg. There was a significant correlation between 
closure time (measured by PFA-100; collagen/epinephrine cartridge) and bleeding time 
after aspirin (r=0.78; p<0.01, n=6). 
 
The inhibition of AA-induced platelet aggregation in whole blood was time and dose-
dependent during aspirin treatment. The inhibitory effects of low dose aspirin (37.5 mg 
daily) were significantly attenuated after 24 h compared to 6 h (p<0.01). 24 h after  
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high-dose aspirin (320 mg daily) the aggregatory response to 1 mM AA was almost 
normalized in whole blood. 
 
Collagen-induced (1 µg/mL) platelet aggregation in whole blood with normal 
extracellular calcium levels was inhibited <40% at all dosages. Higher collagen 
concentrations (3 and 5 µg/mL) yielded nearly maximal platelet aggregation in 
hirudinized whole blood despite treatment with aspirin (all dosages). 
 
The nocturnal excretion of 11-dehydro-TxB2 was reduced by 74.0±2,0 % (p<0.001) 
after 37.5 mg aspirin. Four hours after 960 mg aspirin the excretion of 11-dehydro-
TxB2 was reduced by 83.9±2.8 % (p<0.001 vs baseline and 37.5 mg), but there was a 
significant recovery after <24 hours to 78.5±1.4 % inhibition (p<0.001). 
 
Aspirin treatment reduced the urinary excretion of PGI-M by approximately 25% 
already with the lowest aspirin dose. There was a significant recovery of the 
prostacyclin metabolite excretion <24 hours after 960 mg aspirin. We found no 
relationship between changes in the excretion of PGI-M and any platelet function 
variable.  
 
As shown in Figure 6, the parameter most sensitive to inhibition by aspirin was AA-
induced platelet aggregation in PRP, followed by serum TxB2. The urinary excretion of 
11-dehydro-TxB2 was less markedly, but dose-dependently reduced by aspirin. 
Inhibition of collagen induced aggregation in hirudinized whole blood was also found 
with the lowest collagen concentration tested (1µg/mL). 
 
The effectiveness of aspirin is thus highly dependent on the method used to evaluate its 
antiplatelet effect. Anticoagulation by hirudin resulted in limited inhibition by aspirin 
of collagen and AA-induced platelet aggregation in whole blood. AA-induced platelet 
aggregation occurred even after 960 mg aspirin if the AA-concentration was high.  
 
A problem with in vitro studies of platelet function in PRP is that centrifugation of 
blood may remove the largest and most active platelets along with the red and white 
blood cells which are known to influence platelet behaviour [204-206]. The less 
pronounced antiaggregatory effect of aspirin treatment in whole blood compared to 
PRP may reflect erythrocyte enhancement, extraplatelet sources of PGH2 and/or 
transcellular formation of TxA2 despite efficient inhibition of COX in platelets. 
Nucleated cells are capable of regenerating the COX-1 enzyme after a couple of hours 
and provide PGH2 to platelets to bypass the inhibition of platelet COX-1 [207]. 
 
We found less pronounced inhibition of 11-dehydro-TxB2 excretion compared to serum 
TxB2  and partial recovery of 11-dehydro-TxB2 excretion at the end of the dosing 
interval indicating that aspirin insensitive (presumably non-platelet) thromboxane 
synthesis had occurred in vivo. 
 
In conclusion aspirin provides only weak inhibition of platelet aggregation in whole 
blood with normal calcium levels despite effective platelet COX inhibition and there is 
a recovery of platelet function in whole blood with a normal 24 h dosing interval in 
healthy volunteers. 
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Figure 5: Comparison of AA-induced aggregation (final concentrations 0.2, 0.5 and 1.0 
mM) in whole blood anticoagulated with hirudin after different doses of aspirin. Blood 
samples were taken 1.5-2, 4-6 and 24 hours after latest ingested dose. Low-dose is 37.5 
mg/day for 10 days (filled symbols). High-dose is 320 mg/day for 7 days and a single 
dose of 640 mg taken immediately after the 1.5-2 hour sample (open symbols).  
* p<0.05, ** p<0.01, *** p<0.001 by paired t-tests. 
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Figure 6: Comparison of platelet inhibition afforded by aspirin at different doses (37.5-
960 mg) using different platelet function assays. Illustrated in the graph are: platelet 
aggregation in whole blood (WB) using arachidonic acid (AA; 0,5 mM) or collagen 
(Coll; 1 µg/mL); platelet aggregation in platelet rich plasma (PRP) using AA (1,0 mM) 
as agonists; serum (S) TxB2; and 11-dehydro thromboxane B2 (U-TxM) metabolite 
excretion in urine. 
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4.3 THROMBOXANE METABOLITE EXCRETION DURING PREGNANCY 
– INFLUENCE OF PREECLAMPSIA AND ASPIRIN TREATMENT. 
(PAPER III) 
 
The urinary excretion of 11-dehydro-TxB2 increased with the duration of normal 
pregnancy (fig.7). Three months after delivery the excretion was decreased to lower 
values than those found early in pregnancy. 
 
The urinary excretion of 11 -dehydro-TxB2 was significantly higher in patients at high 
risk of developing preeclampsia compared to the control group (129±12 vs 90±12 
ng/mmol creatinine; p<0.05) before gestational week 13. These findings are in 
agreement with the postulated role for thromboxane in preeclampsia [208]. 
 
Aspirin treatment suppressed 11-dehydro-TxB2 excretion to the same relative extent 
(by approximately 80 %) in pregnant women at high risk of suffering preeclampsia as 
previously found with the same methodology in healthy volunteers (Paper 1,II), and by 
Benigni et al in pregnancies at risk for pregnancy-induced hypertension [209]. Four of 
the 28 high-risk patients developed preeclampsia with increases in blood pressure and 
proteinuria. These patients had a higher excretion of 11-dehydro-TxB2 before 
gestational week 13 than patients without complications (202±38 vs 117±10 ng/mmol 
creatinine p<0.01). The degree of inhibition by aspirin was at least as great in patients 
developing preeclampsia. 
 
Our study thus shows increased 11-dehydro-TxB2 excretion already before gestational 
week 13 in patients at high risk for preeclampsia compared to healthy pregnant women. 
These data imply that the elevation of thromboxane production, and the imbalance 
between thromboxane and prostacyclin which has been found in women with a high 
risk of suffering preeclampsia or actually manifesting the disease [210-212], 
commences very early in pregnancy. Thus, aspirin treatment should probably be started 
very early to increase the chance of influencing the development of preeclampsia by 
reducing platelet-dependent thromboxane formation.  
 
Non-platelet dependent thromboxane formation may also be of importance in 
preeclampsia. Walsh et al [208] showed that trophoblast cells in preeclamptic placentas 
produced 7 times as much thromboxane as prostacyclin. Of interest is that trophoblast 
cells, in contrast to platelets, can regenerate COX-1. Furthermore, the trophoblast cells 
may not be exposed to effective concentrations of aspirin during low-dose treatment 
due to the efficient first-pass metabolism of aspirin noted above. 
 
In summary, the present results indicate that 11-dehydro-TxB2 excretion increases 
throughout normal pregnancy with the highest levels 3-7 days postpartum. Patients at 
high risk of suffering preeclampsia have an increased 11-dehydro-TxB2 excretion 
compared to healthy pregnant women already before gestational week 13. Low-dose 
aspirin treatment (75 mg once daily) effectively inhibits platelet-dependent 
thromboxane production early in pregnancy, but the 11-dehydro-TxB2 excretion 
increases later in pregnancy. These data imply that the modest effects of aspirin seen in 
preeclampsia prevention trials may be related to late initiation of therapy. The use of 
very low doses of aspirin (< 75 mg daily) may have contributed to the findings in trials. 
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Figure 7:  Left panel: Urinary excretion of 11-dehydro-thromboxane B2 (U-TxM) in 22 
healthy pregnant women during and after pregnancy. Right panel: Urinary excretion of 
TxM before and after two weeks of aspirin treatment in 24 patients at high risk for 
preeclampsia (filled columns) and 4 patients who actually developed preeclampsia 
(open columns). Mean values and SEM. P-values were obtained with paired t-tests. 
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4.4 PROTHROMBOTIC RESPONSES TO EXERCISE ARE LITTLE 
INFLUENCED BY CLOPIDOGREL TREATMENT 
 
In study IV 15 healthy volunteers performed exhaustive exercise without and with 
clopidogrel pretreatment (75 mg/day; 7 days). The workload achieved in the exercise 
test was approximately 260 W on both occasions.  
 
Exercise evoked platelet activation in vivo as reflected by increased circulating platelet-
platelet aggregates (PPAs) (p<0.001 by ANOVA), shortened filtragometry readings 
(p<0.001), increased P-selectin expressing single platelets (p<0.001), and elevated 
levels of 11-dehydro-TxB2 in plasma (p<0.001). Exercise also enhanced the platelet 
responsiveness to ADP or thrombin in vitro (p<0.001 for both by ANOVA). These 
effects of exercise are in agreement with previous results [195]. 
 
Clopidogrel treatment effectively inhibited platelet ADP-receptors as the P-selectin 
expression response to 10-5 M ADP in vitro was reduced by 72± 2.7 % (range 54-85 
%), indicating good compliance and efficient blockade of P2Y12 receptors. Clopidogrel 
treatment also attenuated the responses to thrombin but did not significantly attenuate 
the enhancing effect of exercise (p=0.20 with ADP and p=0.19 with thrombin as 
platelet agonists). Attenuation of agonist-stimulated platelet activation in vitro by 
clopidogrel may reflect positive feed-back by platelet-released ADP in response to 
submaximal stimulation by other platelet agonists [137,168,213]. This may have 
implications in the vicinity of the locally formed thrombi, even though it does not seem 
to influence the function of circulating platelets. 
 
Clopidogrel treatment reduced platelet aggregability assessed by filtragometry (p<0.05) 
both at rest and following exercise but there was no significant effect of clopidogrel 
treatment on the enhancement of platelet reactivity to agonist stimulation by exercise 
(P=0.53 by two-factor repeated measures ANOVA). The prolongation of filtragometry 
readings by clopidogrel treatment at rest suggests that such measurements reflect an 
ADP-dependent component in platelet activation. 
 
Exercise enhanced thromboxane formation as evidenced by measurements of 11-
dehydro-TxB2 in plasma, whereas urinary measurements could not detect any exercise 
effect. Urinary measurements are thus less sensitive than measurements in plasma 
when assessing responses to short-lasting stimuli in vivo. The elevation of 11-dehydro-
TxB2 in plasma probably reflects platelet activation during exercise, as most of the 
thromboxane metabolite emanates from platelets [202]. However, a small contribution 
from other cells such as monocytes cannot be ruled out. 
 
Exercise increased circulating PLAs mainly due to leukocytosis, as the percentages of 
PLAs among leukocytes changed little. Plasma elastase was markedly elevated by 
exercise (p<0.001 by ANOVA) indicating increased granulocyte secretion but was not 
influenced by clopidogrel treatment. Clopidogrel treatment did not influence the basal 
CD11b expression either before or after exercise among total leukocytes, neutrophils or 
monocytes, but attenuated responses of total leukocytes and neutrophils to ADP 
(p<0.05). Monocyte CD11b expression also increased with ADP stimulation but this 
response was not attenuated by clopidogrel treatment. Clopidogrel treatment did not 
influence soluble CD40L levels either at rest or after exercise.  
 
Clopidogrel treatment did not influence circulating PLAs either at rest or after exercise 
but did attenuate the responses to in vitro stimulation by both ADP and submaximal 
thrombin concentrations with regard to platelet-conjugated leukocytes and their 
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subpopulations. Platelet-lymphocyte aggregate responses to ADP stimulation in vitro 
were, however, slightly enhanced (P<0.05) by exercise, and this enhancement was 
attenuated by clopidogrel treatment (P<0.05) suggesting that platelet activation and 
ADP released from activated platelets influence agonist-stimulated PLA formation in 
vitro. These findings may have implications for the development of atherosclerosis 
since platelet conjugation may enhance the recruitment of leukocytes into the 
(dysfunctional) arterial wall [14,214]. 
 
In summary, strenuous exercise evoked multicellular activation vivo and promoted a 
prothrombotic state, but clopidogrel treatment did not attenuate the platelet response to 
exercise. The hypothesis that P2Y12 -receptor dependent mechanisms are of importance 
for exercise induced activation of circulating platelets (perhaps due to increased shear 
stress involving ADP-dependent mechanisms [61]) was not supported in this study. 
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Figure 8: Exercise evoked platelet activation in vivo, as reflected by increased 
circulating platelet-platelet aggregates (PPAs) (p<0.001 by ANOVA), shortened 
filtragometry readings (inversely reflecting platelet aggregability) (p<0.001), increased 
P-selectin expressing single platelets (p<0.001), and elevated levels of 11-dehydro-
thromboxane B2 (TxM) in plasma (p<0.001). Clopidogrel treatment (solid symbols and 
dashed lines) reduced platelet aggregability assessed by filtragometry (p<0.05), but did 
not significantly attenuate any of these indices of platelet activation by exercise, as 
analyzed by two-factor repeated measures ANOVA. 
 
 
4.5 EFFECT OF CLOPIDOGREL TREATMENT ON STRESS-INDUCED 
PLATELET ACTIVATION AND MYOCARDIAL ISCHEMIA IN ASPIRIN-
TREATED PATIENTS WITH STABLE CORONARY ARTERY DISEASE. 
 
In study V we investigated if the addition of clopidogrel treatment to ongoing aspirin 
treatment could attenuate exercise-induced platelet activation and reduce ambulatory 
and/or exercise-induced myocardial ischemia in 31 patients with CAD. The vast 
majority of patients in both randomized treatment groups had three-vessel disease. We 
had planned to include 44 patients but changes in the health care system in Stockholm 
abolished the waiting list for CABG surgery from which the patients were recruited and  
 
 
 32 
made it impossible to include more than 31 patients as we considered it unethical to 
delay surgery for participation in the study.  
 
The workloads achieved and the heart rate responses to exercise were slightly greater, 
and the signs of ischemia during exercise were slightly less pronounced in the placebo 
group compared to the clopidogrel group, both at baseline and during treatment.  
 
At rest, clopidogrel treatment reduced the platelet P-selectin expression induced by 10 
µM ADP in vitro by 22-87% (mean 64%) and attenuated the responses to thrombin 
stimulation in vitro by approximately 35%. Clopidogrel treatment also attenuated 
collagen-induced platelet aggregation (1 µg/ml) by 40±10% (p<0.05). Circulating 
PPAs reflecting platelet micro-aggregation in vivo were uninfluenced by clopidogrel 
treatment at rest. Again, attenuation of responses to other agonists than ADP (i.e., 
collagen and thrombin) in vitro reflects the importance of positive feed-back by 
platelet-released ADP [137,168].  
 
Exercise enhanced the platelet responsiveness to agonist stimulation when assessed as 
the percentage of platelets expressing P-selectin, but there was no significant 
attenuation of the exercise effect by clopidogrel compared to placebo treatment with 
either agonist. The relative inhibition of ADP-induced platelet activation was similar at 
rest and following exercise indicating that the treatment may protect against thrombotic 
event also during stress caused by heavy exertion. 
 
Platelet-conjugated monocytes were reduced by clopidogrel treatment at rest suggesting 
reduced platelet activation in vivo [215], but this may have been confounded by a high 
pretreatment value in the clopidogrel group. 
 
Clopidogrel treatment reduced the PLA response to in vitro stimulation by 1 µM ADP 
by 62±5 % before and 40±4% after exercise (p<0.001 for both). ADP enhanced the 
formation of platelet-conjugated neutrophils, monocytes and lymphocytes in vitro, and 
these responses were antagonized by clopidogrel (p<0.001). The ANOVA showed an 
overall effect of clopidogrel treatment on thrombin responsiveness (p<0.05) but no 
attenuation of the exercise effect (p=0.25) by clopidogrel compared to placebo. 
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Figure 9: Platelet activation (P-selectin positive platelets) upon stimulation in vitro by 
ADP. Without treatment (baseline) and during co-treatment with clopidogrel (left hand 
panels) or placebo (right hand panels). The upper panels are from before exercise (rest) 
and the lower panels are after exercise. As expected, clopidogrel treatment attenuated 
the responses to ADP (p<0.001), but did not significantly attenuate the enhancing effect 
of exercise (p=0.43 by ANOVA). 
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Figure 10: Platelet activation (P-selectin positive platelets) upon stimulation in vitro by 
thrombin. Without treatment (baseline) and during co-treatment with clopidogrel (left 
hand panels) or placebo (right hand panels). The upper panels are from before exercise 
(rest) and the lower panels are after exercise.  Clopidogrel treatment attenuated the 
responses to thrombin (P<0.001), but did not significantly attenuate the enhancing 
effect of exercise (p=0.31 by ANOVA). The inhibitory effect of clopidogrel on 
responses to thrombin presumably reflects inhibition of the positive feed-back caused 
by ADP released from activated platelets. 
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The ECG evaluation of ambulatory or exercise-induced ischemia showed no effect of 
clopidogrel treatment. Neither of the inflammatory markers CRP, Il-6 or sCD40L, were 
affected by clopidogrel compared to placebo treatment. 
 
In summary, clopidogrel treatment inhibited platelet and PLA responses to ADP and 
thrombin stimulation (i.e. platelet released ADP) in vitro but the acute prothrombotic 
response to exercise was little influenced by clopidogrel treatment in aspirin treated 
CAD patients. This indicates that the P2Y12 receptor is not likely to be of importance in 
stress-induced platelet activation caused by heavy exertion. Furthermore, we found no 
support for the hypothesis that release of vasoactive substances from activated platelets 
contributes to myocardial ischemia in patients with stable angina pectoris and CAD 
documented by coronary angiography. 
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4.6 GENERAL DISCUSSION 
 
Antiplatelet therapy with aspirin and clopidogrel is a cornerstone in cardiovascular 
prevention and lowers cardiovascular mortality and morbidity in patient with CAD 
[16,17]. Mental stress and physical exertion can trigger acute coronary events [56] and 
prothrombotic responses to stress may contribute to such triggering [11-13,56]. 
Hemodynamic factors that increase wall stress and inflammatory weakening of the 
fibrous cap of the plaque may result in a plaque rupture exposing a highly 
thrombogenic surface [5]. Activated platelets and coagulation seem to contribute to 
accelerated atherosclerosis [14,216]. 
 
The work presented in this thesis shows that both aspirin and clopidogrel has 
limitations as antithrombotic agents. Recurrent ischemic events occurrence during dual 
antiplatelet therapy including stent thrombosis remains a major clinical problem [21]. 
Numerous pathways are involved in platelet activation and platelets contain storage 
granules with large amounts of prothrombotic, angiogenic, proinflammatory and 
proatherogenic substances released upon activation [87]. 
 
In a previous study a single high dose of aspirin failed to attenuate the prothrombotic 
responses to exercise [195] and in the present work neither clopidogrel alone nor the 
addition of clopidogrel to aspirin treatment influenced the prothrombotic responses to 
exercise. Adrenaline can overcome the effects of aspirin in animal models of arterial 
thrombosis [217] and noradrenaline infusion increases platelet aggregability despite 
aspirin in humans [92]. β1-blockade attenuates the haemodynamic responses to exercise 
but there was no effect on the platelet activation response in patients with stable angina 
[9]. Thus, sympatho-adrenal activation may be of importance, but the exact 
mechanisms responsible for stress-induced platelet activation remain illusive. 
 
Since clopidogrel treatment attenuates platelet activity in vivo at rest but exercise 
counteracts the platelet stabilizing effects of clopidogrel in both healthy volunteers and 
in patients with CAD the hypothesis that ADP and the platelet P2Y12 -receptor is 
involved in stress-induced platelet activation was not supported. However the relative 
inhibition of ADP induced platelet activation by clopidogrel was similar at rest and 
following exercise indicating that treatment protects against thrombotic events also 
during stress.  
 
There is currently considerable interest in issues related to clopidogrel resistance and   
variability of responses to clopidogrel treatment [21,218].  In the present study of CAD 
patients the mean degree of inhibition of ADP-induced platelet activation was 64% but 
the responses varied considerably between patients (from 22-87% inhibition) in 
agreement with previous findings [185,218,219]. In healthy volunteers there was less 
variation as the degree of inhibition of ADP-induced activation was 72 % (range 54-
85%).The variable degree of inhibition of ADP-induced platelet responses by 
clopidogrel treatment may have influenced the possibilities of detecting attenuation of 
platelet activation by heavy exercise, especially in the CAD patients. Therapeutic 
failure manifested by ischemic events has been associated with high on-treatment 
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platelet reactivity [20]. The absolute level of platelet reactivity during treatment is a 
better predictor of thrombotic risk than responsiveness to clopidogrel [21]. 
 
A wide range of “aspirin resistance” or poor responsiveness has been reported [22]. In a 
direct comparison of different functional tests Lordkipanidzé et al found a range that 
”aspirin resistance” varied between 2.8-59.5 % [115]. Several authors have reported an 
increased risk of suffering cardiovascular events [22,137,148,149,220,221] among such 
patients. One explanation for this result may be our finding that there is a recovery of 
platelet function 24 hours after dosing and that pronounced AA-induced platelet 
aggregation could still occur in whole blood despite aspirin treatment. Of interest, 
Spectre et al found that twice daily dosing of aspirin improves platelet inhibition in 
whole blood (AA-induced aggregation) in patients with type 2 diabetes [222]. 
 
There is residual AA-induced platelet activation in patients treated with aspirin. 
Frelinger et al found that this activation was independent of COX-1 and COX-2 and 
mediated in part by ADP induced platelet activation. This finding raises the possibility 
that clopidogrel treatment in addition to its direct antiplatelet effect via the P2Y12 ADP 
receptor also decreases residual arachidonic acid induced platelet activation and that 
this may have clinical implications [223]. Platelet activation by ADP should increase 
AA-release acting as a positive feed-back for platelet activation in a similar manner as 
the ADP-mediated positive feed-back discussed above. Indeed, several authors have 
shown that clopidogrel treatment reduces thromboxane production in vivo and ex vivo 
[224,225]. In our study in healthy volunteers (paper IV), however, clopidogrel did not 
influence either plasma or urinary 11-dehydro-TxB2. This may be due to already low 
thromboxane generation in healthy subjects in contrast to patients with manifest 
vascular disease where thromboxane generation is increased [4,55]. However, 
Helgasson et al had similar negative findings as ours in a study in 30 chronic ischemic 
stroke patients treated with aspirin and clopidogrel [226]. It has recently been proposed 
that aspirin may provide little additional protection against athero-thrombotic events in 
presence of strong P2Y12 receptor blockade [227], but this is speculative since no large 
study has investigated the effect of adding aspirin or placebo to clopidogrel treatment in 
patients with CAD.  Of note, abundant data indicate that stopping aspirin in patients 
with strong need for double antiplatelet drug treatment, such as patients with drug 
eluting coronary artery stents, increases the risk of stent thrombosis [228].  
 
The present work has improved the methodology for immunological measurements of 
11-dehydro-TxB2 in urine, and has also shown that such measurements may be 
performed in plasma for the evaluation of platelet activity. Interestingly, conventional 
analysis of urinary 11-dehydro-TxB2 excretion has been shown to predict future 
complications in aspirin treated patients at high risk of cardiovascular disease [221]. 
Whether our optimized method may be even more efficient with respect to prognostic 
information in patients with risk of cardiovascular complications is not known.  
 
There is no “gold standard” with regard to platelet function testing and a combination 
of several methods probably provides the most reliable results. Using urinary 11-
dehydro-TxB2 and whole blood aggregometry may be a good approach for the 
evaluation of in vivo effects of aspirin treatment. Measurements of AA-induced platelet 
aggregation in PRP and serum TxB2 may provide the most specific assessment of  
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platelet COX inhibition, but more “global” markers of platelet activity may reflect the 
clinical consequences of antiplatelet therapy better [21,229]. Work to improve and 
evaluate global bedside tests should be intensified as clinical research should aim at 
refining treatment and improving prognosis in patients; global tests seem to be the right 
path to choose in this respect.  
 
The relationship between surrogate markers for platelet function and clinical events is a 
critical issue determining the dosing regime. The time dependence of inhibitory effects 
should be considered and the interval between dosing and sampling has to be taken into 
consideration. The ability of aspirin to block platelet COX-1 (“true aspirin resistance”) 
should be clearly distinguished from treatment failure due to the importance of other 
disease mechanisms or factors such as poor compliance, non-specific measurements, 
too long an interval since the last dose, and/or too low a dose when discussing “aspirin 
resistance” [19,147]. 
 
Aspirin and clopidogrel form cornerstones in the treatment of cardiovascular disease. 
The absolute benefit and proportional effects of antiplatelet prophylaxis with low dose 
aspirin are comparable with those of blood pressure lowering with antihypertensive 
drugs and lipid-lowering with statins [137]. Cardiovascular disease is multifactorial and 
it is not surprising that only about 25 % of all vascular complications can be prevented 
by aspirin [55]. However, defining the optimal aspirin dosing interval for each patients 
group and establishing well documented means of monitoring individual patients may 
further improve the prevention of cardiovascular disease by antiplatelet drugs.  The 
present thesis shows some limitations of aspirin and clopidogrel and also suggests a 
treatment regimen that deserves to be tested in clinical studies of cardiosvascular 
disease, i.e. low dose aspirin twice daily.   
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5 SUMMARY AND CONCLUSIONS 
The following conclusions may be drawn from the studies:  
 
• Measurements of 11-dehydro-TxB2 in urine and plasma are of considerable 
interest when evaluating platelet activity in vivo. An improved sample work-up 
procedure combined with a modified commercially available EIA has been 
developed and evaluated. A key feature of the assay is to keep 11-dehydro-
TxB2 in its open ring form during the entire assay by equilibrating at pH 8.6 
which improved the recovery in and sensitivity of the assay. Large clinical 
studies using this optimized methodological approach are, however, lacking. 
 
• Aspirin provides weak inhibition of platelet aggregation in whole blood with 
normal calcium levels, despite effective platelet COX inhibition. There is 
recovery of thromboxane-dependent platelet activation in whole blood within a 
normal 24 h dosing interval during aspirin treatment. Considering that the 
incidence of myocardial infarction is highest in the early morning hours, i.e. 
when antiplatelet effects of last aspirin dose usually are the lowest, this finding 
may be of clinical importance. 
 
• Several factors have to be taken into consideration when assessing platelet 
function; the anticoagulant used may artifactually modify platelet responses, 
and it is important to distinguish between measurements of specific treatment 
effects (i.e., whether the “drug target” is effectively inhibited) and more non- 
specific or “global” measurements of platelet activation which may be of 
pathophysiological and prognostic importance. Measurements in whole blood 
are more physiological than measurements in PRP, and may provide clinically 
relevant information.  
 
• There is no single ”gold standard” platelet function test for the monitoring of 
aspirin treatment. Urinary 11-dehydro TxB2 and whole blood aggregation may 
provide valuable estimates of “global” in vivo effects of treatment, whereas 
AA-induced aggregation in PRP and S-TxB2 provide specific data on platelet 
COX-inhibition. 
 
• Compared to healthy pregnant women, patients at high risk of suffering 
preeclampsia have an increased thromboxane formation, as assessed by 11-
dehydro-TxB2 excretion, already before gestational week 13. Low-dose aspirin 
treatment (75 mg once daily) effectively inhibits platelet-dependent 
thromboxane production early in pregnancy. 
 
• Clopidogrel treatment attenuates platelet activity in vivo at rest and during 
exercise, but ADP is not important for the enhancement of platelet reactivity by 
exercise in healthy volunteers or in aspirin treated patients with CAD. 
 
• Addition of clopidogrel to aspirin treatment did not attenuate either exercise 
induced or ambulatory ischemia in coronary artery disease patients. 
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• Individualized antiplatelet therapy, based on point-of-care platelet function tests 
that are well validated, may improve cardiovascular prevention by allowing the 
tailoring of doses and dose intervals of the antiplatelet agents used to the needs 
of the individual patient. However, this approach must also be shown to be 
beneficial regarding clinical outcomes before general use. 
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